RVTY Q2 2025: 32% SaaS growth offsets China DRG, 2%-4% guidance
- Strong Signals Software Performance: The company’s signals software business delivered record orders with 32% organic growth and achieved 115% net retention, demonstrating strong recurring revenue and a growing SaaS business.
- Resilient Life Sciences Segment: The life sciences side shows robustness with its reagents business having grown for five consecutive quarters, underscoring stable, ongoing demand from pharma and biotech customers.
- Aggressive Share Repurchase & Capital Allocation: The firm repurchased nearly $450 million of stock in the first half of the year—reducing total shares by about 4%—which supports EPS growth and reflects management’s confidence in the business.
- China DRG Impact: The debundling policy in China is negatively affecting the high-margin immunodiagnostics business, leading to volume declines that could compress margins and erode revenue guidance .
- Tariff Uncertainty: The evolving tariff environment, including the potential shift to a 15% EU tariff, introduces additional cost pressures that could further squeeze margins .
- Lowered Guidance & Weak Segments: The revised full-year organic growth outlook of 2%-4%, coupled with continued underperformance in academic and government segments, raises concerns about the company’s ability to sustain its financial performance under challenging conditions .
| Metric | YoY Change | Reason |
|---|---|---|
Total Revenue | +4.1% | The overall revenue increase to $720 million from $691.7 million is driven primarily by robust gains in the Life Sciences segment, which helped offset a decline in Diagnostics. This contrasts with earlier periods where modest improvements in Diagnostics (up 3% in Q1 2025 ) and minimal Life Sciences growth (1% in Q1 2025 ) were observed, suggesting recent internal initiatives or favorable market conditions have boosted overall sales. |
Life Sciences Revenue | +16.6% | A marked jump from $313.8 million to $366 million indicates a strong turnaround, likely due to a surge in software revenue and other strategic actions that have reversed the earlier modest growth (1% increase in Q1 2025 ). This significant increase reflects both an internal focus on higher-margin offerings and possible improvements in market sentiment compared to previous quarters. |
Diagnostics Revenue | -6.3% | Despite earlier quarters showing positive trends (with a 3% increase in Q1 2025 driven by gains in immunodiagnostics and reproductive health ), the drop from $378.0 million to $354 million in Q2 2025 may be attributed to unfavorable product mix shifts or renewed external market headwinds. This decline suggests that challenges in segments such as applied genomics, which had struggled before , persisted into the current period. |
| Metric | Period | Previous Guidance | Current Guidance | Change |
|---|---|---|---|---|
Organic Growth | Q3 2025 | 2% to 4% | 0% to 2% | lowered |
Revenue | Q3 2025 | $700 to $715 | $690 to $705 | lowered |
Adjusted EPS | Q3 2025 | $1.13 to $1.15 | $1.12 to $1.14 | lowered |
Average Diluted Share Count | Q3 2025 | 119 | 116 | lowered |
Adjusted Operating Margins | Q3 2025 | no prior guidance | 26% | no prior guidance |
Tax Rate | Q3 2025 | no prior guidance | 18% | no prior guidance |
Organic Growth | FY 2025 | 3% to 5% | 2% to 4% | lowered |
Revenue | FY 2025 | $2830 to $2870 | $2.84 billion to $2.88 billion | raised |
Adjusted EPS | FY 2025 | $4.90 to $5.00 | $4.85 to $4.95 | lowered |
Adjusted Operating Margins | FY 2025 | 27.9% to 28.1% | 27.1% to 27.3% | lowered |
Adjusted Tax Rate | FY 2025 | 19% | 18% | lowered |
Net Interest and Other Expense | FY 2025 | $75 | $80 million | raised |
Average Diluted Share Count | FY 2025 | 119 | 117 | lowered |
| Topic | Previous Mentions | Current Period | Trend |
|---|---|---|---|
Signals Software Performance & SaaS Growth | Earlier calls showed solid Signals performance with 20%+ organic growth and gradual SaaS conversion in Q1 2025 , strong Q4 2024 growth and ARR/APV improvements , and a dip in Q3 2024 due to renewal timing. | Q2 2025 reported exceptional performance with over 30% organic growth, its largest quarter of orders, and robust SaaS metrics including a 21% uplift and 115% net retention. | Improvement and recovery from earlier mixed performance with a more positive sentiment and stronger growth signals. |
Diagnostics Business & Screening Segments | Q1 2025 indicated 5% organic growth in Diagnostics, strong immunodiagnostics, and expanding partnerships, while Q4 2024 reported high single‐digit growth in reproductive health and robust newborn screening; Q3 2024 noted moderate growth with regional variations. | Q2 2025 showed modest overall growth of Diagnostics (2%-3% organic) but emphasized challenges in China due to DRG policy, while screening segments like newborn screening continued to perform strongly. | Consistent performance overall but with persistent regulatory challenges in China; sentiment remains mixed with strengths in screening offset by headwinds in Diagnostics. |
Life Sciences Segment Dynamics (Reagents Growth vs Instruments Decline) | Q1 2025 highlighted solid low single-digit reagents growth with declining instrumentation, Q4 2024 detailed mid-single-digit reagents gains against high single-digit instrument declines, and Q3 2024 reiterated stable reagents growth versus pressured instrumentation sales. | Q2 2025 reaffirmed the pattern with continued robust reagents growth (noted as five consecutive quarters) alongside low single-digit declines in instrumentation sales. | Recurring theme with a stable balance between positive reagents performance and instrumentation challenges; sentiment remains balanced. |
Tariff Impacts and Mitigation Strategies | Q1 2025 detailed a gross tariff impact of approximately $135 million and comprehensive mitigation measures including supply chain adjustments, while Q3 2024 discussed readiness for potential tariff changes with a “China for China” strategy; Q4 2024 did not address tariffs. | Q2 2025 continued to stress tariff-related headwinds—highlighting potential EU tariff increases and a gross impact of $0.03–$0.05 on earnings—while emphasizing significant operational cost actions and strategic mitigation steps. | Sustained focus on mitigating tariff effects; while the measures have evolved, the risk remains a constant, keeping sentiment cautious. |
China Market Challenges (DRG Impact, Instrumentation Sales Delays) | Q1 2025 mentioned a resilient Diagnostics business in China with a “China for China” model and noted instrumentation challenges, Q3 2024 focused on significant delays in instrument purchases linked to stimulus uncertainty, and Q4 2024 outlined moderate pricing headwinds due to DRG impacts along with recovery expectations for instrumentation. | Q2 2025 emphasized the impact of the DRG policy causing a reduction in diagnostic panel volumes and predicting high-teen declines in immunodiagnostics along with continued instrumentation sales delays, marking a pronounced headwind. | Persistent and increasingly significant challenge; the regulatory changes in China are exerting greater downward pressure, with sentiment turning more negative. |
Academic and Government Spending Weakness | Q1 2025 saw a pullback in U.S. academic spending impacting instrumentation and consumables, Q4 2024 noted minimal exposure with NIH funding impacts limited, and Q3 2024 reported low single-digit declines in these segments. | Q2 2025 continued to report low single-digit declines in sales to academic and government customers globally, affirming that this weakness remains consistent. | Stable but concerning; the persistent weakness in this segment shows no signs of recovery, maintaining a steady negative sentiment. |
Operating Margins and Financial Performance | Q1 2025 delivered strong margins (25.6%) with above-expectation EPS and healthy free cash flow, Q4 2024 recorded high adjusted margins (up to 30.3% in the quarter) with robust EPS and free cash flow conversion, and Q3 2024 noted margin improvements and debt reduction. | Q2 2025 reported adjusted operating margins at 26.6%, slightly lower due to FX and diagnostics volume pressures, though revenue and EPS remain in line with expectations. | Slight pressures compared to previous periods; while performance remains solid, margins are under some stress from headwinds, resulting in a more cautious tone. |
Capital Allocation and Strategic Investments | Q1 2025 demonstrated disciplined capital allocation via consistent share repurchases and an active M&A pipeline, Q3 2024 emphasized strong share buybacks and debt reduction, and Q4 2024 continued an aggressive share repurchase program with solid free cash flow. | Q2 2025 maintained this disciplined approach with nearly $450 million of share repurchases year-to-date and an active, though selective, evaluation of M&A opportunities. | Consistent and robust approach across periods; the focus remains on strong capital discipline and strategic investments, supporting a positive long-term sentiment. |
Macroeconomic, FX, and Regulatory/Geopolitical Risks | Q1 2025 highlighted a dynamic macro environment with FX headwinds and significant tariff risks (e.g., $135 million impact), while Q3 2024 noted neutral FX effects and emerging signs of recovery despite geopolitical uncertainties, and Q4 2024 maintained a cautious outlook amid FX and regulatory uncertainties. | Q2 2025 described a challenging macro environment with a 1% FX tailwind, persistent regulatory risks (notably due to tariffs and DRG in China), and ongoing geopolitical uncertainties impacting the business. | Risks remain persistent; while mitigation measures are in place, the overall environment stays challenging with cautious sentiment continuing across periods. |
-
China Impact
Q: How did DRG affect China revenue?
A: Management explained that the revised guidance reflects mainly the DRG policy in China, which is expected to lower test volumes until the review anniversary, with no significant impact from VBP, and they are actively working with stakeholders to address the issue. -
Margin Outlook
Q: What are next year’s margin expectations?
A: They expect a baseline operating margin of 28% next year, with potential expansion of 50–75 basis points depending on organic growth, indicating cautious optimism despite current headwinds. -
Revenue Pacing
Q: How is revenue pacing evolving?
A: Management noted that revenue pacing has followed a normal seasonal pattern, with a high single-digit ramp anticipated in Q4, partly driven by a Gel product ramp-up and volume differences between Q3 and Q4. -
Diagnostic Volumes
Q: When will single plex panels help margins?
A: They indicated that although the current debundling is reducing multiplex test volumes, over time the shift to higher-priced single plex tests should gradually offset the losses, though timing remains uncertain. -
Life Sciences Trends
Q: What drives reagent and instrument trends?
A: Management highlighted five consecutive quarters of reagent growth in the pharma-biotech segment, signaling strong underlying demand despite modest weaknesses in capital equipment orders. -
Software Performance
Q: How strong is software business growth?
A: The signals software business delivered over 30% organic growth with record orders, driven by a robust SaaS component and impressive net retention of about 115%, underscoring its resilience. -
Foreign Currency Effects
Q: What drives FX impact on margins?
A: The team attributed margin pressures partly to a significant weakening of the U.S. dollar, which, while creating a revenue tailwind of around 1%, has also exerted material pressure on margins. -
Tariff Impact
Q: What is the estimated impact of EU tariffs?
A: With the updated EU tariffs at 15% (up from 10%), management estimates a gross impact of roughly $0.03–$0.05 per share; however, they are already implementing measures to mitigate these effects. -
Capital Deployment
Q: What is the approach on share repurchases and M&A?
A: The company continues its aggressive repurchase strategy—having bought back nearly $450M in H1—and remains disciplined in evaluating M&A opportunities, only moving forward with targets that meet rigorous financial criteria. -
Genomics Contract
Q: What are the expectations from the Genomics England contract?
A: They reported strong early ramp-up with the contract, anticipating around 10M in volume contributions in the back half of the year, with most activity expected in Q4.
Research analysts covering REVVITY.